Clinical Trial Update: Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of recombinant human growth hormone in children with Short Bowel Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Short Bowel Syndrome

Drugs mentioned

• Somatropin (somatropin)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Short Bowel Syndrome | Phase 3 | Status: COMPLETED